Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it has entered into an Capital Increase Agreement for a private placement of common shares for gross proceeds of CNY 45 million on January 18, 2022. The transaction will include participation from new investors Shanghai Yanli Biotechnology Co., Ltd. for CNY 17.5 million for a 35% stake, Jisheng (Shanghai) Investment Management Co., Ltd. for CNY 7.5 million for a 15% stake and returning investor Vcanbio Cell & Gene Engineering Corp., Ltd for CNY 20 million to hold 50% stake in the company post the transaction. Post the transaction, the registered capital of the company will increase from CNY 5 million to CNY 50 million.